| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Monday’s Close |
|---|---|---|---|---|---|
| INCY | Incyte Corporation | $67.04 | $14.25B | N/A |
What's in Store for Merck in 2019 After a Solid Run in '18?
http://www.zacks.com/stock/news/347164/whats-in-store-for-merck-in-2019-after-a-solid-run-in-18?cid=CS-ZC-FT-347164
Jan 14, 2019 - Merck (MRK) looks well poised for 2019, carrying forward the momentum achieved last year.
0
4 Biotechs That Are Potential Buyouts Post Celgene Deal
http://www.zacks.com/stock/news/346180/4-biotechs-that-are-potential-buyouts-post-celgene-deal?cid=CS-ZC-FT-346180
Jan 08, 2019 - We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2019.
0
Merck Buys NASH Candidate, Keytruda Wins 5 Approvals in Japan
http://www.zacks.com/stock/news/345648/merck-buys-nash-candidate-keytruda-wins-5-approvals-in-japan?cid=CS-ZC-FT-345648
Jan 04, 2019 - Merck (MRK) exercises option to in-license an insulin sensitizer from NGM Biopharmaceuticals for NASH and type II diabetes. Its key drug Keytruda snaps up five new label expansion nods in Japan.
0
Merck's sBLA for Keytruda in Lung Cancer Gets Extended Review
http://www.zacks.com/stock/news/344112/mercks-sbla-for-keytruda-in-lung-cancer-gets-extended-review?cid=CS-ZC-FT-344112
Dec 21, 2018 - FDA extends review period for label expansion application for Merck's (MRK) Keytruda in first-line lung cancer by three months. A decision is now expected in April 2019.
0
Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY
http://www.zacks.com/stock/news/343701/biotech-stock-roundup-pipeline-updates-from-vrtx-amgn-adro-teams-up-with-lly?cid=CS-ZC-FT-343701
Dec 19, 2018 - A busy week for the biotech sector with quite a few licensing deals and other regulatory updates.
0
Here Are Biotech’s Big Pipeline Disappointments in 2018
https://www.fool.com/investing/2018/12/18/here-are-biotechs-big-pipeline-disappointments-in.aspx?source=iedfolrf0000001
Dec 18, 2018 - A number of companies suffered setbacks this year.
0
Incyte (INCY) Collaborates with Innovent for 3 Candidates
http://www.zacks.com/stock/news/343302/incyte-incy-collaborates-with-innovent-for-3-candidates?cid=CS-ZC-FT-343302
Dec 17, 2018 - Incyte (INCY) collaborates with Innovent for the development of three clinical-stage product candidates: pemigatinib, itacitinib and parsaclisib.
0
Roche to Create Companion Diagnostic Test for Merck's Keytruda
http://www.zacks.com/stock/news/342512/roche-to-create-companion-diagnostic-test-for-mercks-keytruda?cid=CS-ZC-FT-342512
Dec 12, 2018 - Roche (RHHBY) signs collaboration agreement with Merck for developing a companion diagnostic test to identify patients for treatment with the latter's Keytruda.
0
5 Top Drug/Biotech Merger & Acquisition Targets for 2019
http://www.zacks.com/stock/news/342034/5-top-drug-biotech-merger-acquisition-targets-for-2019?cid=CS-ZC-FT-342034
Dec 10, 2018 - Here are five stocks that are attractive and most likely to be takeout targets in 2019.
0
Incyte (INCY) Announces Positive Data on Jakafi for GVHD
http://www.zacks.com/stock/news/341138/incyte-incy-announces-positive-data-on-jakafi-for-gvhd?cid=CS-ZC-FT-341138
Dec 04, 2018 - Incyte (INCY) announces positive data on lead drug Jakafi at the ASH meet for the indication of acute GVHD.
0